Breast cancer (BC) is a heterogeneous cancer with multiple subtypes affecting women
worldwide. Triple-negative breast cancer (TNBC) is a prominent subtype of BC with poor …

There are promising new therapeutic agents for CRC patients, including novel small-
molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC's …

Colorectal cancer (CRC) is the most common gastrointestinal malignancy in the USA and
approximately 50% of patients develop metastatic disease (mCRC). Despite our …

Background Although cancer immunotherapy is one of the most effective advanced-stage
cancer therapies, no clinically approved cancer immunotherapies currently exist for …

We report herein the design, synthesis, and biological investigation of a series of novel Pt
(IV) prodrugs with non-steroidal anti-inflammatory drugs naproxen, diclofenac, and …

At present, colorectal cancer (CRC) has become a serious threat to human health in the
world. Dipeptidyl peptidase 3 (DPP3) is a zinc-dependent hydrolase that may be involved in …

Mounting evidence has demonstrated that angiogenesis plays an important role in tumour
progression. However, the key regulators in tumour angiogenesis remain unclear. Recently …

Natural killer cell engagers gained enormous interest in recent years due to their potent anti-
tumor activity and favorable safety profile. Simultaneously, chicken-derived antibodies …

Employing targeting ligands on the surface of liposomes has the great potential to improve
therapeutic efficacy and decreases off-target effects of liposomal formulations. In the present …

Although the colorectal cancer (CRC) mortality rates are decreasing in virtue of CRC
screening and improved therapeutic methods, CRC is still a leading cause of cancer deaths …